U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Clinical Pharmacology Considerations for Novel Therapeutic Modalities - 12/04/2024
  1. News & Events for Human Drugs

Virtual | Virtual

Event Title
Clinical Pharmacology Considerations for Novel Therapeutic Modalities
December 4, 2024

Date:
December 4, 2024
Time:
1:00 p.m. - 3:00 p.m. ET

Topics & PresentationsSpeakers
Clinical Pharmacology Considerations for Novel Therapeutic Modalities 
Intro – Novel Therapeutic ModalitiesRajanikanth Madabushi, Ph.D.
Associate Director
Guidance & Policy Team
Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS) | CDER
Final Guidance: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics – Part 1Hobart Rogers, PharmD, Ph.D.
Captain, United States Public Health Service
Reviewer
Division of Translational and Precision Medicine (DTPM)
OCP | OTS | CDER
Final Guidance: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics – Part 2Anuradha Ramamoorthy, Ph.D. FCP
Master Scientist & Policy Lead
Guidance & Policy Team
OCP | OTS | CDER
Q&A Session 1Rajanikanth Madabushi, Hobart Rogers, Anuradha Ramamoorthy,

and

Wendy Wu, Ph.D.
Senior Pharmacokineticist
Division of Applied Regulatory Sciences
OCP | OTS | CDER 

Oluseyi Adeniyi, Pharm.D, Ph.D.
Reviewer
DTPM | OCP | OTS | CDER
Final Guidance: Clinical Pharmacology Considerations for Antibody-Drug ConjugatesSarah Ridge, Ph.D.
Policy Analyst
Guidance & Policy Team
OCP | OTS | CDER
Final Guidance: Clinical Pharmacology Considerations for Assessment of Intrinsic Factors QTC, Immunogenicity, and DDIQin Sun, Ph.D.
Biologics Lead
Therapeutic Biologics Program
OCP | OTS | CDER
Q&A Session 2Sarah Ridge, Qin Sun,

and

Brian Booth, Ph.D.
Director
Division of Cancer Pharmacology I
OCP | OTS | CDER | FDA

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS EVENT (Hosted by CDER SBIA)

This webinar will discuss the clinical pharmacology considerations for the development of novel therapeutic modalities. To support the growing number of novel therapeutics, the final guidances on oligonucleotide therapeutics and antibody-drug conjugates will be highlighted and described in detail.

Our FDA subject matter experts will also address the unique considerations for oligonucleotide therapeutics and antibody-drug conjugates with respect to topics such as dose selection, exposure/response analysis, organ impairment, drug interactions, QTc assessment, and immunogenicity. The presenters will communicate when the recommendations described in the guidances should be considered and what types of assessments are suitable to address the topics listed above during drug development.

INTENDED AUDIENCE

  • Scientists in pharmaceutical companies, contract research organizations, and consultant firms who work on developing novel therapeutic modalities
  • Regulatory reviewers and policy makers working in those areas

TOPICS COVERED

  • Overview of novel therapeutics
  • Clinical pharmacology considerations for oligonucleotide therapeutics
  • Clinical pharmacology considerations for antibody drug conjugates

LEARNING OBJECTIVES

  • To gain an understanding of the clinical pharmacology considerations and recommendations for the development of:
    • oligonucleotide therapeutics
    • antibody-drug conjugates

FDA RESOURCES

Back to Top